Overview: NGS Megaloencephalic Leuko Sequencing TestIntroduction: The NGS Megaloencephalic Leuko Sequencing Test sequences genes to diagnose megaloencephalic leukoencephalopathy (MLC), causing brain swelling or motor issues. Aligned with 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected MLC.
Other Names: MLC Assay, MLC1/HEPACAM Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: MLC sequencing began in the 2000s with leukodystrophy research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose MLC, guides treatment, and evaluates patients with brain swelling or motor issues.
Test Parameters: 1. MLC Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of brain swelling, motor issues, or MLC symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document brain swelling, motor issues, macrocephaly, or family history of MLC. Include current medications, especially anticonvulsants.
Consent: Written consent required, detailing the tests purpose, MLC implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze MLC genes (e.g., MLC1, HEPACAM). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for MLC diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm MLC, guiding supportive care or genetic counseling. Negative results may require brain MRI.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Brain MRI, EEG, or neurological exam to confirm MLC diagnosis.
Test Limitations: Not all MLC cases are detected; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Leukodystrophy Guidelines, 2023; Neurology, van der Knaap MS, 2022.
